Skip to content
StockMarketAgent
Direct answer
UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation. Fair value range: low $230, high $450, with mid-point at $340.
Stock analysis

UNH UnitedHealth Group Incorporated fair value $340–$450

UNH
By StockMarketAgent.AI team· supervised by
Đã phân tích: 2026-05-08Cập nhật tiếp theo: 2026-08-08Methodology v2.4Archetype: Mature compounderNYSE · Health Care
View archive
Giá
$378.06
▼ -38.07 (-10.07%)
Giá trị hợp lý
$340
$340–$450
Khuyến nghị
Giảm
confidence 88/100
Tiềm năng tăng
-10.1%
upside to fair value
Biên an toàn
$288.99
buy below · 15%
Vốn hóa thị trường
$343.3B
P/E fwd 18.2
Dự phòng tiếng AnhVI
Hiển thị bản gốc tiếng Anh trong khi đang dịch
Báo cáo này chưa được dịch. Hãy làm mới sau vài phút khi hàng đợi dịch xử lý xong.

§1 Tóm tắt điều hành

  • UNH offers unmatched scale in healthcare but currently faces acute near-term margin pressure.
  • Valuation models heavily cap aggressive extrapolations, yielding a grounded $339.99 fair value.
  • The current price of $378.07 embeds growth expectations that risk a multiple de-rating.
Fair value
$340
Margin of safety
-11.2%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$378.07Price
FV $339.99
High $449.63

UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation.

  • Cycle upside
    Favorable regulatory environments, stable utilization rates, and rapid adoption of value-based care.

§2 Kịch bản tiêu cực

A severe stress test assumes operating margins structurally compress to 4.2% without recovery, dragging ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. below WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. and stalling free cash flow generation indefinitely.

Các cách luận điểm này có thể đổ vỡ

Permanent MA Rate Cuts

· Medium

Regulatory agencies structurally enforce severe Medicare Advantage rate cuts, permanently destroying UNH margin profiles.

FV impact
Severe reduction to the low-end $230 fair value range.
Trigger
12-24 months

Runaway Medical Inflation

· Medium

Utilization rates remain permanently elevated while value-based care initiatives fail to offset the structural MCR deterioration.

FV impact
Midpoint collapses below $300 due to EPS and FCF stagnation.
Trigger
6-18 months

Antitrust Optum Breakup

· Low

Aggressive regulatory intervention forces the spin-off or severe operational firewalling of Optum from UnitedHealthcare.

FV impact
Sustained multiple compression and loss of integrated scale synergies.
Trigger
36-60 months
Tín hiệu cảnh báo sớm cần theo dõi
Chỉ sốHiện tạiNgưỡng kích hoạt
Medical care ratio consistently exceeds the 84% threshold.MonitorDeterioration versus the report thesis
Optum Health revenue growth decelerates below 5% annually.MonitorDeterioration versus the report thesis
Operating margins fail to breach the 6% normalized assumption.MonitorDeterioration versus the report thesis
Regulatory changes successfully cap Medicare Advantage profitability.MonitorDeterioration versus the report thesis
Free cash flow conversion persistently drops below net income.MonitorDeterioration versus the report thesis

§3 Lịch sử tài chính

Báo cáo kết quả kinh doanh — sáu kỳ gần nhất
Khoản mụcT−0T−1T−2T−3T−4CAGR
Kỳ2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
Doanh thu$287.60B$324.16B$371.62B$400.28B$447.57B+11.7%
Lợi nhuận gộp$69.65B$79.62B$90.96B$89.40B$82.92B+4.5%
Lợi nhuận hoạt động$23.97B$28.44B$32.36B$32.29B$18.96B-5.7%
Lợi nhuận ròng$17.29B$20.12B$22.38B$14.41B$12.06B-8.6%
EPS (pha loãng)$18.08$21.18$23.86$15.51$13.23-7.5%
EBITDA$27.07B$31.84B$36.33B$28.08B$23.06B-3.9%
R&D
SG&A

Điểm chất lượng

Điểm Piotroski F
6 / 9
Điểm chất lượng tổng hợp 0–9
Điểm Altman Z
2.97
Rủi ro phá sản (>3 an toàn)
OCF / Lợi nhuận ròng
1.63×
>1 cho thấy chất lượng lợi nhuận cao
Cổng chất lượng kế toán
Pass
Cổng điều chỉnh theo ngành
ROIC
8.6%
Tỷ suất sinh lời trên vốn đầu tư
Phần 3

Numbers analysis

Người đăng ký cá nhân — từ §411 phần nữa

Đọc phân tích đầy đủ — 11 phần nữa.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Báo cáo đầy đủ cho mọi mã được phủ
Lưu trữ khuyến nghị 24 tháng
Bản tin watchlist + cảnh báo thay đổi khuyến nghị
Xuất PDF + DOCX bằng mọi ngôn ngữ
Bắt đầu dùng thử miễn phí
Hủy bất kỳ lúc nào.
FAQ

UNH — frequently asked questions

  1. Based on our latest analysis, UNH screens modestly overvalued. The current price is $378 versus a composite fair-value midpoint of $340 (range $230–$450), which implies roughly 10.1% downside to the midpoint.
Related coverage

Names readers of UNH also follow

Same archetype: mature-compounder
Same sector: Health Care